ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer

被引：0
|
作者：
Mc Leer, A. [1 ]
Duruisseaux, M. [2 ]
Pinsolle, J. [2 ]
Dubourg, S. [1 ]
Mondet, J. [1 ]
Phillips-Houlbracq, M. [2 ]
Magnat, N. [1 ]
Faure, J. [3 ]
Chatagnon, A. [3 ]
de Fraipont, F. [1 ]
Levra, M. Giaj [2 ]
Toffart, A. C. [2 ]
Ferretti, G. [4 ]
Brambilla, E. [5 ]
Hainaut, P. [1 ]
Moro-Sibilot, D. [2 ]
Lantuejoul, S. [5 ]
机构：
[1] Hop Michallon, CHU Grenoble, Canc Mol Genet Platform, La Tronche, France
[2] Hop Michallon, CHU Grenoble, Thorac Oncol, La Tronche, France
[3] Hop Michallon, CHU Grenoble, Mol Biol Platform, La Tronche, France
[4] Hop Michallon, CHU Grenoble, Radiol & Imaging Dept, La Tronche, France
[5] Hop Michallon, CHU Grenoble, Dept Pathol, La Tronche, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1336P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
    Pirker, Robert
    Filipits, Martin
    ESMO OPEN, 2019, 4 (05)
  • [42] Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
    Tang, Hao
    Jin, Longyu
    Zhang, Zhang
    Jiang, Zhibin
    Malik, Zeeshan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip
    Jarvis, John
    Kageleiry, Andrew
    Culver, Kenneth
    Wu, Eric Q.
    Wakelee, Heather
    CANCER EPIDEMIOLOGY, 2015, 39 (03) : 307 - 312
  • [44] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    MEDICAL ONCOLOGY, 2015, 32 (06)
  • [45] EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas
    Shinmura, Kazuya
    Kageyama, Shinji
    Igarashi, Hisaki
    Kamo, Takaharu
    Mochizuki, Takahiro
    Suzuki, Kazuya
    Tanahashi, Masayuki
    Niwa, Hiroshi
    Ogawa, Hiroshi
    Sugimura, Haruhiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2010, 1 (02) : 271 - 275
  • [46] Treatment of brain metastases in ALK-positive non-small cell lung cancer
    Ceddia, Serena
    Codacci-Pisanelli, Giovanni
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 165
  • [47] How I treat ALK-positive non-small cell lung cancer
    McCusker, Michael G.
    Russo, Alessandro
    Scilla, Katherine A.
    Mehra, Ranee
    Rolfo, Christian
    ESMO OPEN, 2019, 4
  • [48] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [49] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [50] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
12345